Risk of acute pancreatitis in patients with inflammatory bowel disease

Czech version

Authors: P. Dítě ^1-3 ; D. Solil ^1,2 ; Magdalena Uvírová ⁴ ; T. Kupka ^3,5 ; M. Konečný ¹ ; J. Dolina ^1,2 ; Bohuslav Kianička ^2,6
Authors‘ workplace: Interní gastroenterologická klinika, FN Brno ¹; Lékařská fakulta MU, Brno ²; Lékařská fakulta OU, Ostrava ³; EUC Laboratoře CGB a. s., Ostrava ⁴; Oddělení gastroenterologie, hepatologie a pankreatologie, Interní a kardiologická klinika, FN Ostrava ⁵; II. interní klinika, FN u sv. Anny v Brně ⁶
Published in: Gastroent Hepatol 2026; 80(1): 36-38
Category: IBD: Review Article
doi: https://doi.org/10.48095/ccgh202636

Overview

Acute pancreatitis is more prevalent in inflammatory bowel disease (IBD) patients in comparison with the healthy population. The most frequent cause of acute pancreatitis in IBD patients is medication therapy, especially with thiopurines and mesalazine, and rarely due to other medications. Symptomatology of acute pancreatitis might by caused by a 2^nd type of autoimmune pancreatitis, which is associated more frequently with ulcerative colitis. Cholethiasis is more prevalent in patients with Crohn’s disease due to malabsorption of bile acids after ileo-colonic resection. There is a reason that acute biliary pancreatitis is more prevalent in Crohn’s disease patients compared to ulcerative colitis. In most cases, the course of acute pancreatitis in the IBD population is mild with edematous structural changes in the pancreas, which can be completely resolved.

Keywords:

inflammatory bowel disease – ulcerative colitis – Crohn’s disease – acute pancreatitis – autoimmune pancreatitis

Sources

1. Iang W, Du Y, Xiang C et al. Age period –⁠ cohort analysis of pancreatitis epidemiological trends from 1990 to 2019 and forecasts 2044: a systematic analysis from global Burden of Disease Study 2019. Front Publ Health 2023; 11 : 1118888. doi: 10.3389/fpubh.2023.1118888.

2. Zheng F, Li J, Ma L et al. Acute pancreatitis risk in the diagnosis and management of inflammatory bowel disease: a critical focus. Open Med 2025; 20 (1): 20251189. doi: 10.1515/med-2025-1189.

3. Cai QY, Tan K, Zhang XL et al. Incidence, prevalence and comorbidities of chronic pancreatitis: s 7-year population-based study. World J Gastroenterol 2023; 29 (30): 4671–4384. doi: 10.3748/wjg.v29.i30.4671.

4. Schneider S, Hirth M, Weiss C et al. Prevalence of inflammatory bowel disease in alcoholic, non-alcoholic and autoimune pancreatitis. Z Gastroenterol 2018; 56 (5): 469–478. doi: 10.1055/s-0043-123881.

5. Tél B, Stubnya B, Gede N et al. Inflammatory bowel disease elevate the risk of developing acute pancreatitis: a meta-analysis. Pancreas 2020; 49 (9): 1174–1186. doi: 10.1097/MPA. 0000000000001650.

6. Lee H, Lee E, Do GY et al. Histone deacetylase inhibitor MGCD00103 protects the pancreas from streptozotocin-induced oxidative and beta-cells death. Biomed Pharmacother 2019; 109 : 921–929. doi: 10.1016/j.biopha.2018.10.163.

7. Venkatesh K, Glenn H, Delaney A et al. Fire in the belly: a scoping review of the imunopathological mechanisms of acute pancreatitis. Front Immunol 2022; 13 : 1077414. doi: 10.3389/fimmu.2022.1077414.

8. Kim JW, Hwang SW, Park SH et al. Clinical course of ulcerative colitis in patients who develop acute pancreatitis. World J Gastroenterol 2017; 23 (19): 3505–3512. doi: 10.3748/wjg.v23.i19.3505.

9. Ng WK, Wong SH, Ng SC et al. Changing epidemiological tends of inflammatorybowel disease in Asia. Intest Res 2016; 14 (2): 111–119. doi: 10.5217/ir.2016.14.2.111.

10. Barthet M, Hastier P, Bernard JP et al. Chronic pancreatitis an inflammatory bowel disease: true or coincidental association? Am J Gastroent 1999; 94 (8): 2141–2148. doi: 10.1111/ j.1572-0241.1999.01287.x.

11. Rothfuss KS, Stange EF, Herrlinger KR. Extraintestinal manifestations and complications in inflammatory bowel diseases. World J Gastroenterol 2006; 12 (30): 4819–4831. doi: 10.3748/wjg.v12.i30.4819.

12. Bernejo F, Lopez Sanroman A, Taxonera C et al. Acute pancreatitis in inflammatory bowel disease with special reference to azathioprine-induced panreatitis. Aliment Pharmacol Ther 2008; 28 (5): 623–628. doi: 10.1111/j.1365-2036.2008.03746.x.

13. Inoue H, Shiraki K, Okano H et al. Acute pancreatitis in patients with ulcerative colitis. Dig Dis Sci 2005; 50 (6): 1064–1067. doi: 10.1007/s10620-005-2705-7.

14. Ueki T, Kawamoto K, Otsuka Y et al. Prevalence and clinicopathological features of autoimmune pancreatitis in Japanese patients with inflammatory bowel disease. Pancreas 2015; 44 (3): 434–440. doi: 10.1097/MPA.0000000000000261.

15. Park SH, Kim D, Ye BD et al. The characteristics of ulcerative colitis associated with autoimmune pancreatitis. J Clin Gastroenterol 2013; 47 (6): 520–525. doi: 10.1097/MCG.0b013e31827fd4a2.

16. Bellocchi MC, Mottes MC, Blesl A et al. Acute pancreatitis in inflammatory bowel disease: results from the European Pandora Study. Medicina 2025; 61 (9): 1532. doi: 10.3390/medicina6091532.

17. Banks PA, Bollen TE, Dervenis C et al. Classification of acute pancreatitis –⁠ 2012: revision of the Atlanta classification and definition by international consensus. Gut 2013; 62 (1): 102–111. doi: 10.1136/gutjnl-2012-302779.

18. Sanderson E, Glymour MM, Holmes MV et al. Mendelian randomization. Nat Rev Methods Primers 2022; 2 : 6. doi: 10.1038/43586-021-00925-5.

19. Lei Y, Zang L, Liu S et al. Parabacteroides produces acetate to alleviate heparanase-exacerbate acute pancreatitis through reducing neutrophil infiltration. Microbiome 2021; 9 (1): 115. doi: 10.1186/s40168-021-01065-2.

20. Chang CC, Chiou CS, Lin HL et al. Increased risk of acute pancreatitis in patients with rheumatoid arthritis: a population-based cohort study. PLoS One 2015; 10 (8): e0135187. doi: 10.1371/journal.pone.0135187.

21. Hong R, Li Z, Li M et al. Hepatobiliary and pancreatic manifestations in inflammatory bowel disease: an umbrella review of metaanalyses. Ther Adv Gastroenterol 2025; 18 : 17562848241311165. doi: 10.1177/17562848241311165.

Doručeno/Submitted: 12. 12. 2025

Přijato/Accepted: 22. 12. 2025

Korespondenční autor prof. MUDr. Petr Dítě, DrSc.

Interní gastroenterologická klinika

LF MU a FN Brno

Jihlavská 20

625 00 Brno

Pdite.epc@gmail.com